Literature DB >> 11720009

Matrix metalloproteinase and cytokine profiles in monocytes over the course of stroke.

M Kouwenhoven, C Carlström, V Ozenci, H Link.   

Abstract

Stroke is a common cause of death and disability in our society. Stroke is associated with changes in immune responses within the central nervous system as well as systemically. The cells contributing to such changes as well as the factors contributing to formation of the inflammatory infiltrate observed in stroke remain to be clarified. In this study, blood monocytes and corresponding mononuclear cells (MNC) were separated and examined in parallel within 4 days and 1-3 months after onset of ischemic stroke. Numbers of TNF-alpha-, IL-12-, IL-6-, and IL-10-secreting cells and of cells expressing mRNA for matrix metalloproteinase (MMP)-1, -2, -7, -9 and tissue inhibitor of MMP (TIMP)-1 were studied. The TNF-alpha-, IL-12-, and IL-6-secreting monocytes and MNC were elevated during the acute phase compared to healthy controls. Such differences were not observed when stroke patients were examined during convalescence. The IL-10-secreting monocytes did not change over the course of stroke. Levels of monocytes expressing MMP-1, MMP-7 and TIMP-1 mRNA were elevated in the acute phase of stroke patients compared to convalescence and healthy controls, as were levels of MMP-1, -2, -7, -9 and TIMP-1 mRNA expressing blood MNC. The MMP-2 and -9 activity as measured by zymography also was higher in MNC supernatants in the acute phase of stroke compared to convalescence. The high levels of proinflammatory cytokines and MMPs in blood monocytes and MNC further demonstrate the presence of systemic aberrations in the acute phase of stroke. Such changes may contribute to the influx of blood-borne cells into the ischemic lesions during the acute phase of stroke.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11720009     DOI: 10.1023/a:1012244820709

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  45 in total

Review 1.  The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases.

Authors:  A J Docherty; J O'Connell; T Crabbe; S Angal; G Murphy
Journal:  Trends Biotechnol       Date:  1992-06       Impact factor: 19.536

2.  The complete primary structure of human matrix metalloproteinase-3. Identity with stromelysin.

Authors:  J Saus; S Quinones; Y Otani; H Nagase; E D Harris; M Kurkinen
Journal:  J Biol Chem       Date:  1988-05-15       Impact factor: 5.157

Review 3.  IL-12 in autoimmunity.

Authors:  R R Caspi
Journal:  Clin Immunol Immunopathol       Date:  1998-07

4.  Phenotype and frequency of cells secreting IL-2, IL-4, IL-6, IL-10, IFN and TNF-alpha in human peripheral blood.

Authors:  E Hagiwara; F Abbasi; G Mor; Y Ishigatsubo; D M Klinman
Journal:  Cytokine       Date:  1995-11       Impact factor: 3.861

5.  Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells.

Authors:  C Czerkinsky; G Andersson; H P Ekre; L A Nilsson; L Klareskog; O Ouchterlony
Journal:  J Immunol Methods       Date:  1988-05-25       Impact factor: 2.303

Review 6.  The role of cytokines in the neuropathology of stroke and neurotrauma.

Authors:  G Z Feuerstein; X Wang; F C Barone
Journal:  Neuroimmunomodulation       Date:  1998 May-Aug       Impact factor: 2.492

7.  Intrathecal release of pro- and anti-inflammatory cytokines during stroke.

Authors:  E Tarkowski; L Rosengren; C Blomstrand; C Wikkelsö; C Jensen; S Ekholm; A Tarkowski
Journal:  Clin Exp Immunol       Date:  1997-12       Impact factor: 4.330

Review 8.  Advances in the vascular pathophysiology of ischemic stroke.

Authors:  G J del Zoppo; J M Hallenbeck
Journal:  Thromb Res       Date:  2000-05-01       Impact factor: 3.944

9.  Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment.

Authors:  V Ozenci; M Kouwenhoven; Y M Huang; P Kivisäkk; H Link
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

10.  Organ-specific autoantigens induce interferon-gamma and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis.

Authors:  J Link; M Söderström; A Ljungdahl; B Höjeberg; T Olsson; Z Xu; S Fredrikson; Z Y Wang; H Link
Journal:  Neurology       Date:  1994-04       Impact factor: 9.910

View more
  5 in total

Review 1.  Progress in the identification of stroke-related genes: emerging new possibilities to develop concepts in stroke therapy.

Authors:  Andrea Lippoldt; Andreas Reichel; Ursula Moenning
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

2.  Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarction.

Authors:  Leonardo Lorente; María M Martín; Luis Ramos; Juan J Cáceres; Jordi Solé-Violán; Mónica Argueso; Alejandro Jiménez; Juan M Borreguero-León; Josune Orbe; José A Rodríguez; José A Páramo
Journal:  BMC Neurol       Date:  2015-07-11       Impact factor: 2.474

3.  Network Pharmacology and Molecular Docking-Based Mechanism Study to Reveal the Protective Effect of Salvianolic Acid C in a Rat Model of Ischemic Stroke.

Authors:  Yuting Yang; Yu He; Xiaoyu Wei; Haitong Wan; Zhishan Ding; Jiehong Yang; Huifen Zhou
Journal:  Front Pharmacol       Date:  2022-01-27       Impact factor: 5.810

Review 4.  Interleukins and Ischemic Stroke.

Authors:  Hua Zhu; Siping Hu; Yuntao Li; Yao Sun; Xiaoxing Xiong; Xinyao Hu; Junjing Chen; Sheng Qiu
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

5.  Association of dimethylarginines and mediators of inflammation after acute ischemic stroke.

Authors:  Shufen Chen; Jens Martens-Lobenhoffer; Karin Weissenborn; Jan T Kielstein; Ralf Lichtinghagen; Milani Deb; Na Li; Anita B Tryc; Annemarie Goldbecker; Qiang Dong; Stefanie M Bode-Böger; Hans Worthmann
Journal:  J Neuroinflammation       Date:  2012-11-17       Impact factor: 8.322

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.